OBJECTIVE: To compare sentinel lymph node (SLN)-positive breast cancer patients who had completion axillary dissection (ALND) with those who did not, with particular attention to clinicopathologic features, nomogram scores, rates of axillary local recurrence (LR), and changes in treatment pattern over time. BACKGROUND: While conventional treatment of SLN-positive patients is to perform ALND, there may be a low-risk subgroup of SLN-positive patients in whom ALND is not required. A multivariate nomogram that predicts the likelihood of residual axillary disease may assist in identifying this group. METHODS: Among 1960 consecutive SLN-positive patients (1997-2004), 1673 (85%) had ALND ("SLN+/ALND") and 287 (15%) did not ("SLN+/no ALND"). We compare in detail the clinicopathologic features, nomogram scores, and rates of axillary LR between groups. RESULTS: Compared with the SLN+/ALND group, patients with SLN+/no ALND were older, had more favorable tumors, were more likely to have breast conservation, had a lower median predicted risk of residual axillary node metastases (9% vs. 37%, P < 0.001), and had a marginally higher rate of axillary LR (2% vs. 0.4%, P = 0.004) at 23 to 30 months' follow-up; half of all axillary LR in SLN+/no ALND patients were coincident with other local or distant sites. For patients in whom intraoperative frozen section was either negative or not done, the rate of completion ALND declined from 79% in 1997 to 62% in 2003 to 2004 but varied widely by surgeon, ranging from 37% to 100%. For 10 of 10 evaluable surgeons, the median nomogram scores in the SLN+/no ALND group were <or=10.5. CONCLUSIONS: SLN+/no ALND breast cancer patients, a selected group with relatively favorable disease characteristics, had a 9% predicted likelihood of residual axillary disease by nomogram but an observed axillary LR of 2%. A gradual and significant decline over time in the rate of completion ALND is associated with, but not entirely explained by, the institution of a predictive nomogram. It is reasonable to omit ALND for a low-risk subset of SLN-positive patients.
OBJECTIVE: To compare sentinel lymph node (SLN)-positive breast cancerpatients who had completion axillary dissection (ALND) with those who did not, with particular attention to clinicopathologic features, nomogram scores, rates of axillary local recurrence (LR), and changes in treatment pattern over time. BACKGROUND: While conventional treatment of SLN-positive patients is to perform ALND, there may be a low-risk subgroup of SLN-positive patients in whom ALND is not required. A multivariate nomogram that predicts the likelihood of residual axillary disease may assist in identifying this group. METHODS: Among 1960 consecutive SLN-positive patients (1997-2004), 1673 (85%) had ALND ("SLN+/ALND") and 287 (15%) did not ("SLN+/no ALND"). We compare in detail the clinicopathologic features, nomogram scores, and rates of axillary LR between groups. RESULTS: Compared with the SLN+/ALND group, patients with SLN+/no ALND were older, had more favorable tumors, were more likely to have breast conservation, had a lower median predicted risk of residual axillary node metastases (9% vs. 37%, P < 0.001), and had a marginally higher rate of axillary LR (2% vs. 0.4%, P = 0.004) at 23 to 30 months' follow-up; half of all axillary LR in SLN+/no ALND patients were coincident with other local or distant sites. For patients in whom intraoperative frozen section was either negative or not done, the rate of completion ALND declined from 79% in 1997 to 62% in 2003 to 2004 but varied widely by surgeon, ranging from 37% to 100%. For 10 of 10 evaluable surgeons, the median nomogram scores in the SLN+/no ALND group were <or=10.5. CONCLUSIONS:SLN+/no ALND breast cancerpatients, a selected group with relatively favorable disease characteristics, had a 9% predicted likelihood of residual axillary disease by nomogram but an observed axillary LR of 2%. A gradual and significant decline over time in the rate of completion ALND is associated with, but not entirely explained by, the institution of a predictive nomogram. It is reasonable to omit ALND for a low-risk subset of SLN-positive patients.
Authors: Jerri S Fant; Michael D Grant; Sally M Knox; Sheryl A Livingston; Kimberly Ridl; Ronald C Jones; Joseph A Kuhn Journal: Ann Surg Oncol Date: 2003-03 Impact factor: 5.344
Authors: Larissa K F Temple; Roberta Baron; Hiram S Cody; Jane V Fey; Howard T Thaler; Patrick I Borgen; Alexander S Heerdt; Leslie L Montgomery; Jeanne A Petrek; Kimberly J Van Zee Journal: Ann Surg Oncol Date: 2002-08 Impact factor: 5.344
Authors: Kimberly J Van Zee; Donna-Marie E Manasseh; Jose L B Bevilacqua; Susan K Boolbol; Jane V Fey; Lee K Tan; Patrick I Borgen; Hiram S Cody; Michael W Kattan Journal: Ann Surg Oncol Date: 2003-12 Impact factor: 5.344
Authors: Arpana M Naik; Jane Fey; Mary Gemignani; Alexandra Heerdt; Leslie Montgomery; Jeanne Petrek; Elisa Port; Virgilio Sacchini; Lisa Sclafani; Kimberly VanZee; Raquel Wagman; Patrick I Borgen; Hiram S Cody Journal: Ann Surg Date: 2004-09 Impact factor: 12.969
Authors: J Michael Guenther; Nora M Hansen; L Andrew DiFronzo; Armando E Giuliano; J Craig Collins; Baiba L Grube; Theodore X O'Connell Journal: Arch Surg Date: 2003-01
Authors: Lee Gravatt Wilke; Linda M McCall; Katherine E Posther; Pat W Whitworth; Douglas S Reintgen; A Marilyn Leitch; Sheryl G A Gabram; Anthony Lucci; Charles E Cox; Kelly K Hunt; James E Herndon; Armando E Giuliano Journal: Ann Surg Oncol Date: 2006-03-02 Impact factor: 5.344
Authors: B Fisher; C Redmond; E R Fisher; M Bauer; N Wolmark; D L Wickerham; M Deutsch; E Montague; R Margolese; R Foster Journal: N Engl J Med Date: 1985-03-14 Impact factor: 91.245
Authors: Umberto Veronesi; Giovanni Paganelli; Giuseppe Viale; Alberto Luini; Stefano Zurrida; Viviana Galimberti; Mattia Intra; Paolo Veronesi; Chris Robertson; Patrick Maisonneuve; Giuseppe Renne; Concetta De Cicco; Francesca De Lucia; Roberto Gennari Journal: N Engl J Med Date: 2003-08-07 Impact factor: 91.245
Authors: I Barco; C Chabrera; A García-Fernández; M Fraile; S González; L Canales; J M Lain; C González; M C Vidal; E Vallejo; J Deu; A Pessarrodona; N Giménez; M García Font Journal: Clin Transl Oncol Date: 2016-11-28 Impact factor: 3.405
Authors: Oldrich Coufal; Tomás Pavlík; Pavel Fabian; Rita Bori; Gábor Boross; István Sejben; Róbert Maráz; Jaroslav Koca; Eva Krejcí; Iva Horáková; Vendula Foltinová; Pavlína Vrtelová; Vojtech Chrenko; Wolde Eliza Tekle; Mária Rajtár; Mihály Svébis; Vuk Fait; Gábor Cserni Journal: Pathol Oncol Res Date: 2009-05-15 Impact factor: 3.201